logo
URAA Taps Into Rising Uranium Demand Amid Booming Interest In AI And Nuclear

URAA Taps Into Rising Uranium Demand Amid Booming Interest In AI And Nuclear

Associated Press7 hours ago

By Kyle Anthony, Benzinga
DETROIT, MICHIGAN - June 24, 2025 ( NEWMEDIAWIRE ) - Among the rising demand for critical minerals is a surge in uranium mining stocks that corresponds to advancements in artificial intelligence (AI) and a push for greater use of nuclear energy. Many people are viewing nuclear energy as a viable source due to its low greenhouse gas profile while also delivering the highest capacity. Essential to nuclear energy is uranium, a heavy metal that can be used as an abundant source of concentrated energy for nuclear reactors.
Growing Demand And Limited Supply
According to the World Nuclear Association, Kazakhstan is the world's largest producer of uranium, supplying approximately 40% of the world's mined uranium. In 2023, as reported by the Financial Times, approximately two-thirds of sales by Kazakhstan's state-owned mining group, Kazatomprom, went to buyers domiciled in Russia, China and the home market. Kazatomprom's January 2025 investor handout noted that 45% of 2023 regional sales were in Asia. With an increasing amount of uranium being sent eastward, understanding the U.S.'s domestic uranium mining capabilities has come to the forefront.
As the U.S. Energy Information Administration (EIA) reported, in 2023, U.S. nuclear generators used 32 million pounds of imported uranium concentrate (U3O8) and only 0.05 million pounds of domestically produced U3O8. Imports of U3O8 came from Canada, Australia, Russia, Kazakhstan and Uzbekistan.
The Trump administration has indicated more significant support for the domestic uranium mining industry, gleaned from the president's executive order declaring a national energy emergency. Furthermore, in 2024, the Department of Energy received $2.7 billion in congressional funding to help revive domestic fuel production for commercial nuclear power plants.
Simply put, the U.S. is making strides to develop domestic uranium capacity, lowering dependence on foreign supply. Regarding future demand for uranium, the World Nuclear Association estimates a 28% increase over 2023-2030. Demand thereafter will depend on new nuclear plants being built and the rate at which older plants are retired. For the decade 2031 to 2040, uranium demand is estimated to increase by 51%.
The Impact Of Trade And AI On Uranium Prices
Recently, uranium prices hit an all-time high due to the increasing energy demand associated with artificial intelligence data centers, which is driving increased demand for nuclear fuel. As reported by the Financial Times, prices for enriched uranium have hit $190 per separative work unit – the standard measure of the effort required to separate isotopes of uranium – compared with $56 three years ago. With many big tech firms beginning to prioritize nuclear power as an energy source, this has resulted in a price increase for uranium.
However, rising trade tensions are poised to impact uranium prices. In a recent earnings call, Grant Isaac, CFO of Cameco, one of the world's largest publicly traded uranium companies, noted that a proposed 10% U.S. tariff on Canadian energy products, including uranium, could lead to significant price inflation in the global uranium market. President Trump's tariffs on Canada are currently in play. As reported by the EIA, approximately 27% of the U.S.'s imported uranium comes from Canada.
Renewed Interest In Nuclear
The increasing demand for electricity has put nuclear energy back in the spotlight. As reported by Bloomberg, there are 61 nuclear power plants under construction globally. Another 90 or so are in the planning stage and more than 300 have been proposed. The proliferation of nuclear plants will require more uranium to be readily available for use. With more nations building nuclear plants as a viable energy source, the demand for uranium is expected to continue to increase.
Trading Uranium With Direxion
For short-term traders looking to gain comprehensive exposure to companies involved in the uranium industry, Direxion's Daily Uranium Industry Bull 2X Shares (URAA) offers enhanced, pure-play exposure to companies involved in the uranium mining industry, which may include mining, exploration, development and production of uranium, or holding physical uranium, owning uranium royalties or engaging in other, non-mining activities that support the uranium mining industry.
URAA is a leveraged ETF designed to track 200% of the daily performance of the Solactive United States Uranium and Nuclear Energy ETF Select Index, before fees and expenses. For investors who are bullish on the uranium industry, this ETF presents a way to engage with seminal companies and participate in their growth patterns. This ETF is best suited for those who can actively manage the inherent risks of leverage and are looking to attempt to capitalize on short-term trends occurring in the uranium industry, and as such, should not be held for more than a day.
Featured image byAjay Pal Singh AtwalonUnsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
This content was originallypublished on Benzinga.Read further disclosureshere.
An investor should carefully consider the Fund's investment objective, risks, charges, and expenses before investing. The Fund's prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain the Fund's prospectus and summary prospectus call 866-476-7523 or visit our website at direxion.com. The Fund's prospectus and summary prospectus should be read carefully before investing.
Direxion Shares Risks – An investment in the Fund involves risk, including the possible loss of principal. The Fund is non-diversified and includes risks associated with the Fund concentrating its investments in a particular industry, sector, or geography which can increase volatility. The use of derivatives such as futures contracts and swaps are subject to market risks that may cause prices to fluctuate over time.
Leverage Risk – The Fund obtains investment exposure in excess of its net assets by utilizing leverage and may lose more money in market conditions that are adverse to its investment objective than a fund that does not utilize leverage. A total loss may occur in a single day. Leverage will also have the effect of magnifying any differences in the Fund's correlation with the Index and may increase the volatility of the Fund.
Daily Index Correlation Risk – A number of factors may affect the Fund's ability to achieve a high degree of correlation with the Index and therefore achieve its daily leveraged investment objective. The Fund's exposure to the Index is impacted by the Index's movement. Because of this, it is unlikely that the Fund will be perfectly exposed to the Index at the end of each day. The possibility of the Fund being materially over- or under-exposed to the Index increases on days when the Index is volatile near the close of the trading day.
Nuclear Energy and Uranium Mining Companies Risk – The price of uranium may be affected by changes in inflation rates, interest rates, monetary policy, economic conditions and political stability. The exploration for uranium and development of uranium mines involves significant financial risks over a significant period of time, which even a combination of careful evaluation, experience and knowledge may not eliminate.
Energy Sector Risk – Energy sector securities may be adversely impacted by changes in the levels and volatility of global energy prices, global supply and demand, and capital expenditures on the exploration and production of energy sources.
Additional risks of each Fund include Effects of Compounding and Market Volatility Risk, Leverage Risk, Market Risk, Counterparty Risk, Rebalancing Risk, Intra-Day Investment Risk, Daily Index Correlation Risk, Other Investment Companies (including ETFs Risk), Cash Transaction Risk, Passive Investment and Index Performance Risk. Please see the summary and full prospectus for a more complete description of these and other risks of the Fund.
Distributor: ALPS Distributors, Inc.
View the original release on www.newmediawire.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

Yahoo

time30 minutes ago

  • Yahoo

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA). The FDA reviewed the first-in-human trial design, including the Company's plan for dose escalation, proposed populations and safety monitoring plan. On the basis of the FDA feedback, the Company, intends to file an IND pending completion of final IND enabling studies. CUE-401 is the Company's lead autoimmune asset, a first-in-class bispecific fusion protein/molecule designed to induce and expand regulatory T cells (Tregs) in vivo through the co-activity of transforming growth factor beta (TGF-β) and a modified variant of interleukin 2 (IL-2). 'We are highly encouraged by the FDA's positive feedback on our proposed development plan for this important program. We believe CUE-401, with its first-in-class mechanism exploiting the combined activities of TGF-β and IL-2 is a potentially disruptive approach differentiated from other Treg-directed therapies, and has the potential to provide durable, long-lasting immune rebalance and tolerance addressing multiple, significant disease indications,' said Daniel Passeri, chief executive officer of Cue Biopharma. Dr. Dan Baker, chief development officer of Cue Biopharma commented, 'CUE-401's mechanistic design extends beyond nTreg proliferation by transforming effector/autoreactive responses to an anti-inflammatory and/or suppressive response, with the prospects of establishing tolerance. The combination of interleukin 2 (IL-2) and transforming growth factor beta (TGF-ß) is considered the 'master switch' for conversion of activated T effector cells into T cells with a regulatory phenotype.' About CUE-401CUE-401 is a preclinical, bispecific fusion protein designed to induce and expand regulatory T cells (Tregs) through the co-activity of modified variants of transforming growth factor beta (TGF-β) and interleukin 2 (IL-2) with therapeutic potential across a range of T-cell mediated autoimmune and inflammatory diseases. CUE-401 has been engineered to harness the Treg induction capacity of TGF-β combined with IL-2 signaling to provide what Cue Biopharma believes to be superior quality and stability of Tregs. The design and specifications of CUE-401 have been guided by leading scientific publications demonstrating that both IL-2 and TGF-β are required for stable and efficient production of active and durable Tregs. CUE-401 is designed to overcome multiple hurdles required to exploit the therapeutic potential of a master switch with a first-in-class, bispecific molecule integrating a masked TGF-ß, with our clinically validated, attenuated IL-2 with an antibody Fc fragment. This novel design provides for 'conditional binding' and avoids off target activity, simplifies manufacturing and has highly differentiated findings in multiple pre-clinical models. In these models, CUE-401 behaves as a master switch to convert autoreactive effector T cells (inflammatory cells) into stable, induced T-regulatory cells (iTregs). These findings suggest that CUE-401 acts by establishing a 'tolerance positive feedback loop' that not only increases nonspecific Treg populations, but critically, reduces and converts specific autoreactive T cells into transdifferentiated iTregs that are specific for the disease-causing autoantigens. About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system without the adverse effects of broad systemic immune in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics. For more information please visit and follow us on X and LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company's expectations regarding the planned IND filing for CUE-401; the Company' expectations regarding the potential characteristics and benefit of CUE-401; the company's belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective modulation of disease-relevant T cell and the applicability of the company's platform across many cancers and autoimmune diseases; and the company's business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as 'believe,' 'expect,' 'may,' 'will,' 'should,' 'would,' 'could,' 'seek,' 'intend,' 'plan,' 'goal,' 'project,' 'estimate,' 'anticipate,' 'strategy,' 'future,' 'likely' or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's pipeline of product candidates and platforms, and its strategies, prospects, plans and objectives are forward-looking statements. Important factors that could cause the company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the Company's ability to successfully advance is development plan for CUE-401; potential setbacks in the company's research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration ('FDA') or other governmental approvals for its product candidates, including FDA clearance of any future IND submission for CUE-401, and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company's trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company's reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company's ability to obtain adequate financing to fund its business operations in the near term; the company's ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Contact Marie Campinell Senior Director, Corporate CommunicationsCue Biopharma, Media ContactJonathan PappasLifeSci Communicationsjpappas@

FromZero.ai Launches Favicon Gallery, Targeting Guinness World Record for Largest Digital Mosaic
FromZero.ai Launches Favicon Gallery, Targeting Guinness World Record for Largest Digital Mosaic

Yahoo

timean hour ago

  • Yahoo

FromZero.ai Launches Favicon Gallery, Targeting Guinness World Record for Largest Digital Mosaic

Interactive online mosaic invites users worldwide to permanently claim custom favicon tiles as part of a record-setting digital artwork San Francisco, California, June 24, 2025 (GLOBE NEWSWIRE) -- today announced the launch of Favicon Gallery, a large-scale digital mosaic project inviting users to permanently claim custom favicon tiles on an interactive online canvas. The project is aiming to set a Guinness World Record for the largest digital mosaic of favicons built in the shortest time. Favicon Gallery by — Guinness World Record mosaic in Gallery features a 100,000-tile digital canvas where each tile can be claimed for $99.99 USD. Participants upload their own favicon image, link, and title, contributing to a growing visual record of internet culture. The project is designed to encourage creativity, community engagement, and bold participation in digital spaces. Created as a public 'from zero' experiment without initial funding or code, Favicon Gallery reflects a philosophy of action over hesitation, demonstrating how ideas can be built openly and collaboratively online. 'Favicon Gallery is a live demonstration of how taking action can drive creativity and progress in the digital world,' said creator Sylvester M. 'We hope this inspires others to contribute, take creative risks, and become part of an evolving piece of internet history.' As the mosaic fills, will formally apply to Guinness World Records for recognition as the world's largest digital favicon mosaic created in the shortest timeframe. The long-term vision is for Favicon Gallery to generate funding that will support future digital ventures and creative innovation through open, community-driven projects. Favicon Gallery transforms the small, often-overlooked favicon, the tiny icon seen in browser tabs, into a platform for digital expression. Each tile in the mosaic represents permanent online real estate, owned and curated by individual participants. The project showcases contributions from creators, entrepreneurs, brands, and communities around the world. Built publicly from day one, Favicon Gallery emphasizes transparency and accessibility. Its development is openly documented on social channels and the project site. Current milestones include reaching 10,000–20,000 claimed tiles as the team builds momentum toward the Guinness World Record Favicon GalleryFavicon Gallery is an interactive digital mosaic created by The platform invites users worldwide to claim custom favicon tiles, contributing to a global artwork that celebrates creativity, internet culture, and bold claim a tile or learn more, visit: Sylvester M. Creator, contact@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

S&P 500 Gains and Losses Today: Coinbase Shares Soar; Oil and Defense Stocks Drop
S&P 500 Gains and Losses Today: Coinbase Shares Soar; Oil and Defense Stocks Drop

Yahoo

timean hour ago

  • Yahoo

S&P 500 Gains and Losses Today: Coinbase Shares Soar; Oil and Defense Stocks Drop

The S&P 500 added 1.1% on Tuesday, June 24, 2025, as optimism spread about a possible de-escalation in the conflict between Israel and Iran. Coinbase shares surged, extending their solid rally as Benchmark analysts boosted their price target on the cryptocurrency exchange operator's stock. The potential for an alleviation of geopolitical tensions contributed to a drop in oil prices, pressuring oil and gas stocks, while aerospace and defense stocks also lost U.S. equities indexes gained ground on Tuesday after President Donald Trump announced a ceasefire agreement between Iran and Israel, raising hopes for a more sustained drawdown in hostilities. Investors also kept an eye on Congressional testimony by Federal Reserve Chair Jerome Powell. Powell indicated that the central bank intends to maintain interest rates at their current levels until there is more clarity on tariff policy and its potential economic impact, despite the White House's calls for immediate rate cuts. The S&P 500 gained 1.1%, closing just beneath its record-high level set in February. The Dow was up 1.2%, while the Nasdaq jumped 1.4%. Shares of Coinbase Global (COIN), operator of the largest cryptocurrency exchange in the U.S., skyrocketed 12.1% on Tuesday to secure the S&P 500's top performance. Analysts at the research firm Benchmark lifted their price target on Coinbase stock, pointing to favorable legislative and regulatory developments and the company's initiatives to capitalize on them. Secretary of Health and Human Services Robert F. Kennedy Jr. announced that the department would launch a massive advertising campaign to encourage the use of wearable health devices. Kennedy specifically mentioned the benefits of glucose monitors for patients managing diabetes. Shares of glucose monitor manufacturer Dexcom (DXCM) surged 9.7%. Uber Technologies (UBER) shares jumped 7.5% as the ridesharing company debuted its robotaxi service in Atlanta. Uber's partnership with Waymo, the autonomous vehicle company owned by Google parent Alphabet (GOOGL), initially offers service in 65 square miles of Atlanta, around half the city's footprint. Carnival Corporation (CCL) posted better-than-expected sales and profits for its fiscal first quarter, and the cruise operator's shares sailed 6.9% higher. The company also boosted its full-year profit outlook, pointing to increases in passengers carried and passenger cruise days as well as declining costs. Shares of competitors Norwegian Cruise Line Holdings (NCLH) and Royal Caribbean Group (RCL) also advanced. AutoZone (AZO) shares dropped 3.6%, losing the most of any S&P 500 stock on Tuesday, following reports that a senior vice president at the auto parts retailer had sold a stake in the company worth more than $2.5 million. Investors often view large sales by company insiders as a negative signal for a stock. Crude oil futures tumbled as optimism around de-escalation in the Middle East helped alleviate potential supply concerns. Shares of energy company Occidental Petroleum (OXY) fell 3.3%, while Exxon Mobil shares (XOM) were down 3%. The potential for calming geopolitical tensions also pressured defense stocks. Northrop Grumman (NOC) shares dropped 3.2%, while shares of aerospace and defense peers RTX Corp. (RTX) and Lockheed Martin (LMT) also traded lower. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store